Figure 6.

Reduced integrin expression increases surface CRT and ERp57. (A) Flow histograms for the indicated integrin expression in WT and β1^−/− cells. (B) Immunoblot assay for expression of integrin β1, CRT, ERp57, and GAPDH in lysates of WT, β1^−/−, and β1^−/− cells re-expressing β1. (C,D) The indicated cells were treated with or without doxorubicin and surface CRT or ERp57 determined by flow cytometry. (E) WT, β1^−/−, and CRT^−/− cells were treated with or without oxaliplatin and surface CRT determined by flow cytometry. (F) Phagocytosis assay for WT, β1^−/−, and CRT^−/− cells treated with oxaliplatin or 9EG7 as indicated. Plots are the mean ± S.D.; n = 3; p-values: *** < 0.001; * < 0.05; ns, not significant.